Sanjivani Paranteral FY26 Annual Report: Revenue declines 7.6% to Rs 64.76 cr
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanjivani Paranteral submitted FY26 Annual Report. Revenue from operations fell 7.61% to Rs 6476.39 lakhs from Rs 7009.86 lakhs. PAT declined to Rs 692.32 lakhs from Rs 810.18 lakhs. EBITDA margin 16.4%, PAT margin 10.7%. Exports contributed 78.5% of revenue. No dividend recommended. Added 4 new geographies, total products 179. Subsidiary SPL Infusion and JV Alevia Healthcare in Czech Republic. Auditors issued unmodified opinion.
Revenue and profit declined year-on-year. No dividend for shareholders. Expansion via new geographies and subsidiaries may support future growth.